Production of drugs using 3D printing technology, the country's first production license landed in Nanjing.

Recently, the Jiangsu Province Drug Administration issued the first national "Drug Production License" for drugs produced using 3D printing technology, marking a crucial step forward in the research and industrialization of 3D printing technology in the pharmaceutical industry in China. This has greatly boosted the confidence of 3D printing technology pharmaceutical companies to continue innovating and developing. The recipient of this license is the 3D printing digital drug production base of Nanjing Sanjili Pharmaceutical Technology Co., Ltd. The base is located in the Jiangning District of Nanjing City in the Life Science Acceleration Zone, including the MED production center, quality control center, and storage center, with an annual production capacity of 300 million 3D printed drugs. It is currently the largest commercial 3D printed drug production capacity base globally.